High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

Advisers to the Centers for Disease Control and Prevention recommended Thursday that influenza vaccines used in the coming flu season be free of the preservative thimerosal, addressing unproven fears ...

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...